MOESM1 of Near infrared fluorescent imaging of brain tumor with IR780 dye incorporated phospholipid nanoparticles

Additional file 1. Figure S1. Histograms of the hydrodynamic size distributions of IR780 encapsulated nanoparticles. Figure S2. NIR absorption spectra of IR780, IR780-liposomes and IR780-phospholipid micelles. Figure S3. NIR fluorescent spectra of IR780-liposomes and IR780-phospholipid micelles. Figure S4. In vivo NIRF signal intensity of IR780-nanoparticles in U87MG ectopic tumors. Figure S5. Representative Ex vivo NIRF images of dissected organs from U87MG ectopic tumor bearing mice. Figure S6. Ex vivo NIRF images of organs and tissues from healthy control mice

Effect of a Pre-Treatment Educational Video in Improving Patient Satisfaction with 5-Fluorouracil Treatment for Actinic Keratoses: A Randomized Controlled Trial

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13555-016-0149-y">https://link.springer.com/article/10.1007/s13555-016-0149-y</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

DataSheet1_Neurobehavioral phenotype of Kabuki syndrome: Anxiety is a common feature.docx

Kabuki syndrome (KS) is a Mendelian Disorder of the Epigenetic Machinery (MDEM) caused by loss of function variants in either of two genes involved in the regulation of histone methylation, KMT2D (34–76%) or KDM6A (9–13%). Previously, representative neurobehavioral deficits of KS were recapitulated in a mouse model, emphasizing the role of KMT2D in brain development, specifically in ongoing hippocampal neurogenesis in the granule cell layer of the dentate gyrus. Interestingly, anxiety, a phenotype that has a known association with decreased hippocampal neurogenesis, has been anecdotally reported in individuals with KS. In this study, anxiety and behavior were assessed in a cohort of 60 individuals with molecularly confirmed KS and 25 unaffected biological siblings, via questionnaires (SCARED/GAS-ID and CBCL/ABCL). Participant age ranged from 4 to 43 years old, with 88.3% of participants having a pathogenic variant in KMT2D, and the rest having variants in KDM6A. In addition, data was collected on adaptive function and positive affect/quality of life in participants with KS using appropriate online surveys including ABAS-III and PROMIS Positive Affect. Survey scores were compared within the KS participants across age groups and between KS participants and their unaffected siblings. We found that children with KS have significantly higher anxiety scores and total behavior problem scores than their unaffected siblings (p = 0.0225, p < 0.0001). Moreover, a large proportion of affected individuals (22.2% of children and 60.0% of adults) surpassed the established threshold for anxiety; this may even be an underestimate given many patients are already treated for anxiety. In this sample, anxiety levels did not correlate with level of cognitive or adaptive function in any KS participants, but negatively correlated with positive affect in children with KS (p = 0.0005). These findings indicate that anxiety is a common neurobehavioral feature of KS. Providers should therefore carefully screen individuals with KS for anxiety as well as other behavioral issues in order to allow for prompt intervention. Neurobehavioral anxiety measures may also prove to be important outcome measures for clinical trials in KS.</p

Perceived symptoms associated with food consumption (%) among asthmatics.

<p>The group with at least one corresponding food allergen sensitization is used as a control group. All p-values refer to comparisons between this group and the others.</p><p>*p < 0.05,</p><p>**p < 0.01,</p><p>***p < 0.001</p><p>Perceived symptoms associated with food consumption (%) among asthmatics.</p

Additional file 1: of Correlates of alcoholics anonymous affiliation among justice-involved women

Self-care scale (DOCX 12 kb

Asthmatics and controls, demographics.

<p>¹Mean ± SEM,</p><p>²Geometric mean (95% CI),</p><p>***p < 0.001</p><p>Asthmatics and controls, demographics.</p

Proportion of subjects with not well-controlled asthma (Panel A) and adjusted odds ratios (age, sex, BMI, FEV₁, levels of FeNO, total IgE, current dose of ICS, current use of ICS/LABA, and current smoking) (Panel B) for not well-controlled asthma in relation to perceived food hypersensitivity and IgE sensitization.

<p>Proportion of subjects with not well-controlled asthma (Panel A) and adjusted odds ratios (age, sex, BMI, FEV₁, levels of FeNO, total IgE, current dose of ICS, current use of ICS/LABA, and current smoking) (Panel B) for not well-controlled asthma in relation to perceived food hypersensitivity and IgE sensitization.</p

Mini-AQLQ- and ACT-scores in relation to perceived food hypersensitivity and IgE sensitization status.

<p>Mini-AQLQ- and ACT-scores in relation to perceived food hypersensitivity and IgE sensitization status.</p

Grouping of asthmatics according to history of perceived food hypersensitivity and IgE sensitization status.

<p>Grouping of asthmatics according to history of perceived food hypersensitivity and IgE sensitization status.</p

Asthmatics with and without perceived food hypersensitivity, divided by IgE sensitization status.

<p>Asthma symptoms in past 12 months. All p-values refer to comparisons between the group without perceived food hypersensitivity and the others.</p><p>*p < 0.05</p><p>Asthmatics with and without perceived food hypersensitivity, divided by IgE sensitization status.</p